Logo

BeiGene's Brukinsa (Zanubrutinib) Receives Health Canada's Approval for Mantle Cell Lymphoma

Share this

BeiGene's Brukinsa (Zanubrutinib) Receives Health Canada's Approval for Mantle Cell Lymphoma

Shots:

  • The approval is based on efficacy results from two studies. The P-II BGB-3111-206 study evaluates zanubrutinib in patients with R/R MCL and showed ORR (84%)- CR (69%)- PR (15%)- mDoR (19.5mos.) @median follow-up time of 18.5mos.
  • The P-I/II BGB-3111-AU-003 study showed ORR (84%) including CR (25%) & PRs (59%)- m-DoR (18.5mos.) @ median follow-up time of 18.8mos. The recommended dose of Brukinsa is either 160mg bid or 320mg- qd- taken orally with/out food
  • The approval marks the second approval of Brukinsa in Canada- following its initial approval in March 2021 for adult patients with WM

 ­ Ref: Businesswire | Image: BeiGene

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions